✦ LIBER ✦

Phase I, pharmacokinetic and pharmacodynamic evaluation of CYT997, an orally-bioavailable cytotoxic and vascular-disrupting agent

✍ Scribed by Matthew Burge, Alessandra B. Francesconi, Dusan Kotasek, Rosa Fida, Gregg Smith, Andrew Wilks, Paul A. Vasey, Jason D. Lickliter

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I trial of CYT997, a novel cytotox

✍ Lickliter, J D; Francesconi, A B; Smith, G; Burge, M; Coulthard, A; Rose, S; Gri 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 563 KB

A phase I pharmacokinetic study of the v

✍ Eskens, F A L M; Tresca, P; Tosi, D; Van Doorn, L; Fontaine, H; Van der Gaast, A 📂 Article 📅 2014 🏛 Nature Publishing Group 🌐 English ⚖ 322 KB

594 A Phase I Dose-escalation, Pharmacok

✍ Bendell, J.; Weiss, G.; Infante, J.; Ramanathan, R.; Jones, S.; Korn, R.; Burris 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 66 KB

An open-label, dose-escalation, safety,

✍ Murakami, H.; Kurata, T.; Onozawa, Y.; Watanabe, J.; Ono, A.; Takahashi, T.; Yam 📂 Article 📅 2014 🏛 Springer 🌐 English ⚖ 474 KB

A randomized, double-blind, placebo-cont

📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 82 KB